NO955059L - Peptides showing oxytocin antagonistic activity - Google Patents

Peptides showing oxytocin antagonistic activity

Info

Publication number
NO955059L
NO955059L NO955059A NO955059A NO955059L NO 955059 L NO955059 L NO 955059L NO 955059 A NO955059 A NO 955059A NO 955059 A NO955059 A NO 955059A NO 955059 L NO955059 L NO 955059L
Authority
NO
Norway
Prior art keywords
antagonistic activity
peptides showing
abu
asn
mpa
Prior art date
Application number
NO955059A
Other languages
Norwegian (no)
Other versions
NO955059D0 (en
Inventor
Carl-Johan Aurell
Per Melin
Anders Nilsson
Jerzy Trojnar
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO955059D0 publication Critical patent/NO955059D0/en
Publication of NO955059L publication Critical patent/NO955059L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Mpa-X-Ile-Y-Asn-a-Abu-NQMeOrn-NH2 (I) (-NH-CH-CO-) CH2 (II) Et peptid med formel (I) hvor Mpa er 3-merkapto- proplonsyreresten (-S-CH22-CH22-CO-): X er D-tryptofan (D-Trp) eller 3-(2-naftyl)-D-alanin (D-Nal); Ike er Isoleucin; Y er allolsoleucin (allolle) eller (S)-2- amino-3-etyl-pentansyre (Ala(e-Et2)); Asn er asparagln; a-Abu er a-aminosmørsyrerest (II) og NaMeOrn er Na- metylornithin, er beskrevet. Peptidene kan bil anvendt som et aktivt ingrediens i et medikament, spesielt i en farmasøytisk sammensetning for terapeutisk behandling ,av omfattende sammentrekninger av livmormuskelen.Mpa-X-Ile-Y-Asn-a-Abu-NQMeOrn-NH 2 (I) (-NH-CH-CO-) CH 2 (II) A peptide of formula (I) wherein Mpa is the 3 S-CH22-CH22-CO-): X is D-tryptophan (D-Trp) or 3- (2-naphthyl) -D-alanine (D-Nal); Ike is Isoleucine; Y is allole soleucine (allele) or (S) -2-amino-3-ethyl-pentanoic acid (Ala (e-Et2)); Asn is asparagine; α-Abu is α-amino butyric acid residue (II) and NaMeOrn is Na-methylornithine is described. The peptides can be used as an active ingredient in a drug, especially in a pharmaceutical composition for therapeutic treatment, by extensive contractions of the uterine muscle.

NO955059A 1993-07-13 1995-12-13 Peptides showing oxytocin antagonistic activity NO955059L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9302414A SE501678C2 (en) 1993-07-13 1993-07-13 Peptide with oxytocin antagonist activity and pharmaceutical composition containing said peptide
PCT/SE1994/000674 WO1995002609A1 (en) 1993-07-13 1994-07-07 Peptides exhibiting oxytocin antagonistic activity

Publications (2)

Publication Number Publication Date
NO955059D0 NO955059D0 (en) 1995-12-13
NO955059L true NO955059L (en) 1995-12-13

Family

ID=20390606

Family Applications (1)

Application Number Title Priority Date Filing Date
NO955059A NO955059L (en) 1993-07-13 1995-12-13 Peptides showing oxytocin antagonistic activity

Country Status (16)

Country Link
EP (1) EP0791012A1 (en)
JP (1) JPH09502427A (en)
KR (1) KR960702848A (en)
CN (1) CN1126999A (en)
AU (1) AU676071B2 (en)
CA (1) CA2163114A1 (en)
CZ (1) CZ9896A3 (en)
FI (1) FI960119A0 (en)
HU (1) HUT74874A (en)
IL (1) IL110267A0 (en)
NO (1) NO955059L (en)
PL (1) PL312568A1 (en)
SE (1) SE501678C2 (en)
TW (1) TW268009B (en)
WO (1) WO1995002609A1 (en)
ZA (1) ZA945090B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604341D0 (en) * 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
EP1480998B1 (en) 2002-02-27 2006-11-22 Ferring BV Intermediates and methods for making heptapeptide oxytocin analogues
CN108290929A (en) 2015-10-06 2018-07-17 辉凌公司 Manufacture the novel method of barusiban and its intermediate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
SE9002384D0 (en) * 1990-07-09 1990-07-09 Ferring Ab DERIVATIVE OF BACKGROUND HORMONES
SE501677C2 (en) * 1993-06-18 1995-04-10 Ferring Bv Biologically active vasopressin analogs, pharmaceutical preparations containing them and their use in the manufacture of drugs

Also Published As

Publication number Publication date
EP0791012A1 (en) 1997-08-27
HUT74874A (en) 1997-02-28
AU7240694A (en) 1995-02-13
KR960702848A (en) 1996-05-23
NO955059D0 (en) 1995-12-13
TW268009B (en) 1996-01-11
SE9302414D0 (en) 1993-07-13
FI960119A (en) 1996-01-10
CN1126999A (en) 1996-07-17
IL110267A0 (en) 1994-10-21
SE9302414L (en) 1995-01-14
FI960119A0 (en) 1996-01-10
CZ9896A3 (en) 1996-06-12
JPH09502427A (en) 1997-03-11
WO1995002609A1 (en) 1995-01-26
CA2163114A1 (en) 1995-01-26
AU676071B2 (en) 1997-02-27
ZA945090B (en) 1995-02-22
PL312568A1 (en) 1996-04-29
SE501678C2 (en) 1995-04-10
HU9503768D0 (en) 1996-02-28

Similar Documents

Publication Publication Date Title
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
GEP20012578B (en) (54) Heteroaryl Succinamides, Pharmaceutical Compositions Containing the Same and Methods for Treatment of the Diseases Caused by Metalloproteinase Activity
IT1252868B (en) ANTI-PHALALGIC PHARMACEUTICAL COMPOSITION FOR ENDONASAL ADMINISTRATION, PROCEDURE TO PREPARE IT AND ITS THERAPEUTIC USE
FI925342A (en) Process for the preparation of therapeutically active (+) - - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol
BR0113643A (en) Guanidinobenzamides compounds as mc4-r agonists and their uses
MY132626A (en) CARBAZOLYL-SUBSTITUTED ETHANOLAMINES AS SELECTIVE ß-3 AGONISTS
HU213098B (en) Process for producing decapeptides antagonistic to hormone for releazing lutheinizing-hormone and pharmaceutical compositions containing them as active components
BRPI9708566A (en) glp-2 analog, glp-human peptide analog, peptide, pharmaceutical composition, use of a glp-2 analog, and, process for identifying intestinetrophic glp-2 analogs.
MY107341A (en) Novel hydroxamic acid and n-hydroxyurea derivatives and their use
CA2250420A1 (en) Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest
MY139203A (en) Pharmaceutical composition
IL72018A (en) Biologically active heptapeptides structurally related to region within growth hormones and pharmaceutical compositions comprising them
AU3850600A (en) Dalda analogs and their use
RO118174B1 (en) Nail polish and use thereof
ES2010561A6 (en) Somatostatin analogue composition and use in treating breast cancer
CA2274686A1 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
TW324662B (en) Benzamide-containing pharmaceutical composition
SE9302124D0 (en) BIOLOGICALLY ACTIVE VASOPRESSIN ANALOGUES
MY106231A (en) Antiviral tetrahydroimidazo [1,4] benzodiazepin-2- thiones.
NO955059L (en) Peptides showing oxytocin antagonistic activity
ATE3416T1 (en) PHARMACOLOGICALLY ACTIVE PEPTIDES AND MEDICATIONS CONTAINING THEM.
TR199801184T2 (en) New compounds with analgesic action.
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
EA200200801A1 (en) Use of follicle-stimulating hormone (FSH) for the treatment of infertility
ES8701784A1 (en) V1-vasopressin antagonists.